Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC)

被引：0
|
作者：
Taylor, Melissa
Reddy, Shilpa
Kumar, Prashanth Ashok
Hariri, Dana
Sokol, Ethan
Sivakumar, Smruthy
Quintanilha, Julia
Pavlick, Dean
Levy, Mia Alyce
Ross, Jeffrey S.
Lustberg, Maryam B.
机构：
[1] Yale New Haven Hosp, New Haven, CT USA
[2] Upstate Univ Hosp, Syracuse, NY USA
[3] SUNY Upstate Univ Hosp, Syracuse, NY USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Fdn Med Inc, Boston, MA USA
[6] Fdn Med, Cambridge, MA USA
[7] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1092
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies
    Bar, Yael
    Fell, Geoffrey
    Dedeoglu, Aylin
    Moffett, Natalie
    Vidula, Neelima
    Spring, Laura
    Wander, Seth A.
    Bardia, Aditya
    Ko, Naomi
    Moy, Beverly
    Ellisen, Leif W.
    Isakoff, Steven J.
    NPJ BREAST CANCER, 2025, 11 (01)
  • [2] Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies
    Bar, Yael
    Dedeoglu, Aylin S.
    Fell, Geoffrey G.
    Moffett, Natalie J.
    Boyraz, Baris
    Ly, Amy
    Bardia, Aditya
    Moy, Beverly
    Ellisen, Leif W.
    Isakoff, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] IMPACT OF HORMONE RECEPTOR STATUS AND HER2 ON SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
    Xiao, H.
    Tan, F.
    Huang, Y.
    Feldman, J.
    Koniaris, L.
    Gummadi, S.
    Adunlin, G. B.
    Ali, A. A.
    VALUE IN HEALTH, 2013, 16 (03) : A131 - A131
  • [4] Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
    Domergue, C.
    Martin, E.
    Lemarie, C.
    Jezequel, P.
    Frenel, J-S.
    Augereau, P.
    Campone, M.
    Patsouris, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S428 - S429
  • [5] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Molecular Characteristics and Prognosis of Triple Negative Breast Cancer Stratified by HER2 Status
    Yang, Xia
    LABORATORY INVESTIGATION, 2024, 104 (03) : S318 - S319
  • [7] Comparison of outcomes of hormone receptor (HR) negative, and HER2 negative (triple negative, TN) to HER2+breast cancer (BC) patients (pts): impact of HER2 status.
    Man, MC
    Moore, D
    Chen, YY
    Rugo, HS
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S142 - S143
  • [8] The Prognostic Impact of HER2-Low and Menopausal Status in Triple-Negative Breast Cancer
    Park, Woong Ki
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeong Eon
    Yu, Jonghan
    Lee, Se Kyung
    Ryu, Jai Min
    Chae, Byung Joo
    CANCERS, 2024, 16 (14)
  • [9] A rapid, non-invasive test to determine HER2-low status in triple negative breast cancer (TNBC) patients
    Cook, Daniel
    Patel, Snehal
    Whitman, John
    Hobbs, Nicole
    Lopez-Ramos, Dorys A.
    Pfeiffer, John
    Peterson, Joseph
    Pandey, Tushar
    Antony, Anuja K.
    Cole, John
    CANCER RESEARCH, 2023, 83 (07)
  • [10] Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
    Domergue, Camille
    Martin, Elodie
    Lemarie, Camille
    Jezequel, Pascal
    Frenel, Jean-Sebastien
    Augereau, Paule
    Campone, Mario
    Patsouris, Anne
    CANCERS, 2022, 14 (10)
12345